OCT 13, 2016 1:32 PM PDT

Limiting Immune Damage from Type 1 Diabetes

WRITTEN BY: Kara Marker
Over seven percent of individuals in the UK with type 1 diabetes are children, and the autoimmune diseases grows more common every year. Using a recombinant version of a chemical naturally produced already in the body, researchers from Cambridge are on the brink of a new treatment for type 1 diabetes that could reduce or even completely eliminate the need for regular insulin injections.
Image credit: Children's Hospital Los Angeles
When the body’s immune cells mistaken the insulin-producing cells of the pancreas, called beta cells, blood glucose levels begin to rise. This what defines type 1 diabetes, and this is what requires individuals with this disease to administer regular insulin shots to regulate blood glucose levels.

A study from the University of Cambridge JDRF/Wellcome Trust Diabetes Inflammation Laboratory at the Cambridge Institute of Medical Research led to the proposition of a new drug to regulate the type 1 diabetes autoimmune response: aldesleukin, a recombinant version of interleukin-2 (IL), a cytokine that wears many hats in the immune system. Aldesleukin is currently approved by the Food and Drug Administration (FDA) to treat melanoma and renal cell carcinoma in high doses.

“The current treatment [for type 1 diabetes] - multiple daily injections of insulin - are at best inconvenient, at worst painful, particularly for children," says Dr Frank Waldron-Lynch, who led the study. "Our goal is to develop a treatment that could see the end to the need for these life-long, daily injections by curtailing the early damage caused by the patient's own immune system.”

Waldron-Lynch and his team conducted their study to measure the ability of aldesleukin to regulate the immune response, using lower doses than the drug is currently used for to treat cancer. In the case of type 1 diabetes, aldesleukin works by enhancing the activity of regulatory T cells, which can limit the immune responses in autoimmune reactions. 

The results from extensive immune monitoring in 40 patients showed that the doses increased the level of regulatory T cells by 10-20 percent, the minimum needed to prevent an immune attack on insulin-producing cells and the maximum level to leave the effector immune cell activity intact in order to keep the rest of the body protected from infection.

Additionally, the results suggest that the drug shouldn’t be administered on a daily basis, so regulatory T cells won’t lose any sensitivity to aldesleukin.

"Our work is at an early stage, but it uses a drug that occurs naturally within the body to restore the immune system to health in these patients,” Waldron-Lynch said. “Whereas previous approaches have focused on suppressing the immune system, we are looking to fine-tune it.” 

In the future, Waldron-Lynch and the team plan on focusing the new aldesleukin-based treatment on people newly-diagnosed with type 1 diabetes who are still able to produce some insulin from beta cells. The study was recently published in PLOS Medicine.
 


Sources: University of Cambridge, American Diabetes Association, National Cancer Institute, Cytokine
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 30, 2020
Immunology
Gene Silencing Therapy Stops the Itch of Psoriasis
JUL 30, 2020
Gene Silencing Therapy Stops the Itch of Psoriasis
A team of Harvard researchers has identified a promising new approach for treating psoriasis — a topical lotion co ...
AUG 17, 2020
Immunology
Nervous Protein Neuromedin B May Prevent Immune Reactivity
AUG 17, 2020
Nervous Protein Neuromedin B May Prevent Immune Reactivity
A protein produced by the nervous system seems to play a role in regulating the immune system. For people with inflammat ...
AUG 25, 2020
Immunology
Targeting Checkpoint Molecule Could Mean Checkmate for Cancer
AUG 25, 2020
Targeting Checkpoint Molecule Could Mean Checkmate for Cancer
In a new study published in Cell, researchers have identified a metabolic enzyme that could have powerful tumor-killing ...
SEP 15, 2020
Immunology
Common Spice Relieves Eye Inflammation in Dogs, Human Studies to Follow
SEP 15, 2020
Common Spice Relieves Eye Inflammation in Dogs, Human Studies to Follow
A therapeutic made from turmeric has been shown to help reduce the effects of a painful inflammatory eye condition in do ...
OCT 17, 2020
Cell & Molecular Biology
Fat Droplets in Cells Help the Immune System Fight Infection
OCT 17, 2020
Fat Droplets in Cells Help the Immune System Fight Infection
Scientists have found that our immune system has a surprising helper: droplets of fat that sit inside cells.
NOV 05, 2020
Immunology
Immune cells from recovered COVID-19 patients can help protect immunocompromised individuals against infection
NOV 05, 2020
Immune cells from recovered COVID-19 patients can help protect immunocompromised individuals against infection
Our knowledge of COVID-19 or SARS-CoV-2 is increasing every day, with new research papers published continuously. Resear ...
Loading Comments...